Metrnl, a secreted protein expressed in white adipose tissue, has been identified as a novel adipokine. It is also highly expressed in barrier tissues, including the skin, intestinal and respiratory tract epithelium in both mice and humans. Research shows that its expression is upregulated by inflammation, chronic high-fat diets, exercise, cold exposure, etc., and it plays important roles in promoting neurite extension, enhancing white fat browning, improving insulin sensitivity, modulating lipid metabolism and regulating inflammatory response, the latter implying Metrnl is a new cytokine. These studies suggest that Metrnl could be a promising biomarker and a potential therapeutic target for the related diseases. For proving this, clinical studies need to be performed to bridge the gap between bench and bedside. In this paper, we summarize the progress in recent clinical research on Metrnl. Most of these clinical studies are designed to confirm the relationship between circulating Metrnl and metabolic or cardiovascular disease (type 2 diabetes and coronary heart disease), or immune inflammation-related diseases, such as colitis, psoriasis and arthritis. Although blood Metrnl seems to fluctuate and are affected by many factors, such as drugs, physical exercise, and cold exposure, these clinical studies provide reliable clues that Metrnl is associated with coronary heart disease, inflammation-related diseases, etc. Nevertheless, the roles of Metrnl in some diseases such as nervous system diseases remain unclear, and its putative involvement should be further clarified. These studies could promote the application of Metrnl in clinic as a new therapeutic target.
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharmacol Sci. 2015;36:461–70.
Li ZY, Zheng SL, Wang P, Xu TY, Guan YF, Zhang YJ, et al. Subfatin is a novel adipokine and unlike meteorin in adipose and brain expression. CNS Neurosci Ther. 2014;20:344–54.
Ushach I, Burkhardt AM, Martinez C, Hevezi PA, Gerber PA, Buhren BA, et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol. 2015;156:119–27.
Li ZY, Fan MB, Zhang SL, Qu Y, Zheng SL, Song J, et al. Intestinal metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides. Acta Pharmacol Sin. 2016;37:1458–66.
Jorgensen JR, Fransson A, Fjord-Larsen L, Thompson LH, Houchins JP, Andrade N, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol. 2012;233:172–81.
Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157:1279–91.
Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. Adipocyte metrnl antagonizes insulin resistance through PPARgamma signaling. Diabetes. 2015;64:4011–22.
Qi Q, Hu WJ, Zheng SL, Zhang SL, Le YY, Li ZY, et al. Metrnl deficiency decreases blood HDL cholesterol and increases blood triglyceride. Acta Pharmacol Sin. 2020. https://doi.org/10.1038/s41401-020-0368-8.
Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37:571–9.
Ushach I, Arrevillaga-Boni G, Heller GN, Pone E, Hernandez-Ruiz M, Catalan-Dibene J, et al. Meteorin-like/Meteorin-beta Is a novel immunoregulatory cytokine associated with inflammation. J Immunol. 2018;201:3669–76.
Wang K, Li F, Wang C, Deng Y, Cao Z, Cui Y, et al. Serum levels of Meteorin-Like (Metrnl) are increased in patients with newly diagnosed type 2 diabetes mellitus and are associated with insulin resistance. Med Sci Monit. 2019;25:2337–43.
Lappas M. Maternal obesity and gestational diabetes decrease metrnl concentrations in cord plasma. J Matern Fetal Neonatal Med. 2019:1–5. https://doi.org/10.1080/14767058.2019.1676713.
Chung HS, Hwang SY, Choi JH, Lee HJ, Kim NH, Yoo HJ, et al. Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes. Diabetes Res Clin Pr. 2018;136:100–7.
Dadmanesh M, Aghajani H, Fadaei R, Ghorban K. Lower serum levels of Meteorin-like/Subfatin in patients with coronary artery disease and type 2 diabetes mellitus are negatively associated with insulin resistance and inflammatory cytokines. PLoS One. 2018;13:e0204180.
Liu ZX, Ji HH, Yao MP, Wang L, Wang Y, Zhou P, et al. Serum Metrnl is associated with the presence and severity of coronary artery disease. J Cell Mol Med. 2019;23:271–80.
Zuo L, Ge S, Ge Y, Li J, Zhu B, Zhang Z, et al. The Adipokine Metrnl ameliorates chronic colitis in Il-10-/- mice by attenuating mesenteric adipose tissue lesions during spontaneous colitis. J Crohns Colitis. 2019;13:931–41.
Bridgewood C, Russell T, Weedon H, Baboolal T, Watad A, Sharif K, et al. The novel cytokine Metrnl/IL-41 is elevated in psoriatic arthritis synovium and inducible from both entheseal and synovial fibroblasts. Clin Immunol. 2019;208:108253.
Miao CY. Introduction: Adipokines and cardiovascular disease. Clin Exp Pharmacol Physiol. 2011;38:860–3.
Zhu X, Zhang HW, Chen HN, Deng XJ, Tu YX, Jackson AO, et al. Perivascular adipose tissue dysfunction aggravates adventitial remodeling in obese mini pigs via NLRP3 inflammasome/IL-1 signaling pathway. Acta Pharmacol Sin. 2019;40:46–54.
AlKhairi I, Cherian P, Abu-Farha M, Madhoun AA, Nizam R, Melhem M, et al. Increased expression of Meteorin-Like hormone in type 2 diabetes and obesity and its association with irisin. Cells. 2019;8:1283.
Lee JH, Kang YE, Kim JM, Choung S, Joung KH, Kim HJ, et al. Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res Clin Pract. 2018;135:7–10.
Zheng SL, Li ZY, Zhang Z, Wang DS, Xu J, Miao CY. Evaluation of two commercial enzyme-linked immunosorbent assay kits for the detection of human circulating Metrnl. Chem Pharm Bull (Tokyo). 2018;66:391–8.
El-Ashmawy HM, Selim FO, Hosny TAM, Almassry HN. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis. Diabetes Res Clin Pract. 2019;150:57–63.
Eaton M, Granata C, Barry J, Safdar A, Bishop D, Little JP. Impact of a single bout of high-intensity interval exercise and short-term interval training on interleukin-6, FNDC5, and METRNL mRNA expression in human skeletal muscle. J Sport Health Sci. 2018;7:191–6.
Saghebjoo M, Einaloo A, Mogharnasi M, Ahmadabadi F. The response of meteorin-like hormone and interleukin-4 in overweight women during exercise in temperate, warm and cold water. Horm Mol Biol Clin Investig. 2018;36:/j/hmbci.2018.36.issue-3/hmbci-2018-0027/hmbci-2018-0027.xml.
Loffler D, Landgraf K, Rockstroh D, Schwartze JT, Dunzendorfer H, Kiess W, et al. METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans. Int J Obes (Lond). 2017;41:112–9.
Wang C, Pan Y, Song J, Sun Y, Li H, Chen L, et al. Serum Metrnl level is correlated with insulin resistance, but not with beta-cell function in type 2 diabetics. Med Sci Monit. 2019;25:8968–74.
Pellitero S, Piquer-Garcia I, Ferrer-Curriu G, Puig R, Martinez E, Moreno P, et al. Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery. Int J Obes (Lond). 2018;42:919–22.
Du Y, Ye X, Lu A, Zhao D, Liu J, Cheng J, et al. Inverse relationship between serum Metrnl levels and visceral fat obesity (VFO) in patients with type 2 diabetes. Diabetes Res Clin Pr. 2020;161:108068.
Fouani FZ, Fadaei R, Moradi N, Zandieh Z, Ansaripour S, Yekaninejad MS, et al. Circulating levels of Meteorin-like protein in polycystic ovary syndrome: a case-control study. PLoS One. 2020;15:e0231943.
Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin. 2019;40:1–8.
Li ZY, Wang P, Miao CY. Adipokines in inflammation, insulin resistance and cardiovascular disease. Clin Exp Pharmacol Physiol. 2011;38:888–96.
Zhang SL, Li ZY, Wang DS, Xu TY, Fan MB, Cheng MH, et al. Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells. Acta Pharmacol Sin. 2020;41:763–70.
Gong W, Liu Y, Wu Z, Wang S, Qiu G, Lin S. Meteorin-like shows unique expression pattern in bone and its overexpression inhibits osteoblast differentiation. PLoS One. 2016;11:e0164446.
Watad A, Cuthbert RJ, Amital H, McGonagle D. Enthesitis: much more than focal insertion point inflammation. Curr Rheumatol Rep. 2018;20:41.
Nishino J, Yamashita K, Hashiguchi H, Fujii H, Shimazaki T, Hamada H. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. EMBO J. 2004;23:1998–2008.
Lee HS, Han J, Lee SH, Park JA, Kim KW. Meteorin promotes the formation of GFAP-positive glia via activation of the Jak-STAT3 pathway. J Cell Sci. 2010;123:1959–68.
Baht GS, Bareja A, Lee DE, Rao RR, Huang R, Huebner JL, et al. Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism. Nat Metab. 2020;2:278–89.
Lee JO, Byun WS, Kang MJ, Han JA, Moon J, Shin MJ, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKalpha2. FEBS J. 2020;287:2087–104.
Jung TW, Lee SH, Kim HC, Bang JS, Abd El-Aty AM, Hacimuftuoglu A, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARdelta-dependent pathways in skeletal muscle of mice. Exp Mol Med. 2018;50:122.
Surace C, Piazzolla S, Sirleto P, Digilio MC, Roberti MC, Lombardo A, et al. Mild ring 17 syndrome shares common phenotypic features irrespective of the chromosomal breakpoints location. Clin Genet. 2009;76:256–62.
This work was supported by grants from the National Natural Science Foundation of China Major Project (No. 81730098), the Medical Innovation Project (No. 16QNP087), and the Shanghai Science and Technology Commission Project (No. 16JC1405100 and No. 201409004600).
The authors declare no competing interests.
About this article
Cite this article
Miao, Zw., Hu, Wj., Li, Zy. et al. Involvement of the secreted protein Metrnl in human diseases. Acta Pharmacol Sin 41, 1525–1530 (2020). https://doi.org/10.1038/s41401-020-00529-9
- secreted protein
- type 2 diabetes
- coronary heart disease
Effects of Increased Physical Activity and/or Weight Loss Diet on Serum Myokine and Adipokine Levels in Overweight Adults with Impaired Glucose Metabolism
Journal of Diabetes and its Complications (2021)